In the phase 1 study of tunlametinib monotherapy for NRAS-mutant melanoma, tunlametinib demonstrated acceptable tolerability and substantial clinical activity as well as favorable PK profiles (Zhao et al., 2022; Wang et al., 2023). Here, NRAS is linked to melanoma.